Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063733 | 0.72 | — | — | |
| SCHEMBL5581551 | 0.71 | TDO2 (0.34) | — | |
| SCHEMBL68884 | 0.68 | NUDT1 (0.44) | ACMSDNR1I2KDM4BCHRM1TBXA2R | |
| SCHEMBL1243063 | 0.68 | KDM4E (0.41) | ACMSDNR1I2KDM4BCHRM1TBXA2R | |
| SCHEMBL14283748 | 0.68 | NUDT1 (0.44) | ACMSDNR1I2KDM4BCHRM1TBXA2R | |
| SCHEMBL929865 | 0.68 | NUDT1 (0.37) | ACMSDNR1I2KDM4BCHRM1TBXA2R | |
| SCHEMBL22313839 | 0.67 | ACMSD (0.53) | ACMSDCNR2BACE1HDAC4HDAC2 | |
| SCHEMBL29890620 | 0.67 | ACMSD (0.53) | ACMSDCNR2BACE1HDAC4HDAC2 | |
| SCHEMBL1777247 | 0.67 | NPC1 (0.38) | NR1I2KDM4BCHRM1TBXA2RADRA1A | |
| SCHEMBL3357755 | 0.67 | ACMSD (0.53) | ACMSDCNR2BACE1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522868-B2 | Tetrakis(ether-substituted formylphenyl) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-8921613-B2 | Polynuclear poly(phenol) family | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20120277479-A1 | NOVEL POLYNUCLEAR POLY(PHENOL) FAMILY | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | AHR, PAH, ALK | ACMSD 1029/4885NR1I2 8/4885KDM4B 1682/4885 |
| US-20120277479-A1 | NOVEL POLYNUCLEAR POLY(PHENOL) FAMILY | PAH, C1S, AP1S1 | ACMSD 1524/4885NR1I2 97/4885KDM4B 2290/4885 |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | AHR, PAH, ARNT | ACMSD 1637/4885NR1I2 41/4885KDM4B 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.